Rigel Pharmaceuticals (RIGL) Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $234.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 59.68% year-over-year to $234.0 million; the TTM figure through Mar 2026 stood at $234.0 million (up 59.68% YoY), while the FY2025 annual figure was $240.2 million, up 77.77% from the prior year.
• Current Assets for Q1 2026 stood at $234.0 million, down from $240.2 million in the prior quarter.
• The five-year high for Current Assets was $240.2 million in Q4 2025, with the low at $92.5 million in Q1 2024.
• The 5-year median for Current Assets is $115.9 million (2022), against an average of $136.9 million.
• The sharpest annual moves came in 2022 and 2025: Current Assets sank 35.45% in 2022, then soared 101.87% in 2025.
• Rigel Pharmaceuticals' Current Assets stood at $115.9 million in 2022, then fell by 14.35% to $99.3 million in 2023, then surged by 36.1% to $135.1 million in 2024, then soared by 77.77% to $240.2 million in 2025, then declined by 2.56% to $234.0 million in 2026.
• Business Quant data shows RIGL's Current Assets at $234.0 million in Q1 2026, $240.2 million in Q4 2025, and $214.9 million in Q3 2025.